ENES YEŞİLBAŞ

Dr. ENES YEŞİLBAŞ

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2025 in European Journal of Cancer
Verified
Journal Article
Closed access
OAOrhun Akdoğan
Orhun Akdoğan
GUGalip Uyar
Galip Uyar
ENES YEŞİLBAŞENES YEŞİLBAŞ
ENES YEŞİLBAŞ
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
NMNuri Alperen Malkoc
Nuri Alperen Malkoc
OSOsman Sutcuoglu
Osman Sutcuoglu

12 January 2026 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
GUGalip Uyar
Galip Uyar
ENES YEŞİLBAŞENES YEŞİLBAŞ
ENES YEŞİLBAŞ
OAOrhun Akdoğan
Orhun Akdoğan
TTTuba Uğur Tuzcu
Tuba Uğur Tuzcu
OSOsman Sutcuoglu
Osman Sutcuoglu


6 October 2025 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
SŞSemra Demirtaş Şenlik
Semra Demirtaş Şenlik
GUGalip Uyar
Galip Uyar
ENES YEŞİLBAŞENES YEŞİLBAŞ
ENES YEŞİLBAŞ
BOBerna Oksuzoglu
Berna Oksuzoglu
OSOsman Sutcuoglu
Osman Sutcuoglu

18 June 2026 in International Journal of Cancer
Verified
Journal Article
Open access
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
GUGalip Uyar
Galip Uyar
ENES YEŞİLBAŞENES YEŞİLBAŞ
ENES YEŞİLBAŞ
FAFatma Zehra Altunç
Fatma Zehra Altunç
DÇDamla Erimhan Çevik
Damla Erimhan Çevik
OSOsman Sutcuoglu
Osman Sutcuoglu
Chemotherapy‐induced peripheral neuropathy (CIPN) is a dose‐limiting toxicity of taxane‐based chemotherapy with limited preventive options. We evaluated whether dual‐site mechanical compression during paclitaxel infusion reduces CIPN in women with gynecologic cancers. In this prospective, intraindividual, self‐controlled study, patients receiving carboplatin–paclitaxel underwent compression of the nondominant hand (two surgical gloves) and ipsilateral lower limb (Class II stocking), while contralateral limbs served as controls. CIPN was assessed using CTCAE v5.0 and EORTC QLQ‐CIPN20 at baseline, Cycle 3, end of treatment (EOT), and 3‐ and 6‐month follow‐up. Among 76 patients (median age, 61 years), moderate‐to‐severe CIPN was observed less frequently in compression limbs than in control limbs at Cycle 3 (35.5% vs. 53.9%; p = 0.001), EOT (59.2% vs. 69.7%; p = 0.021), 3 months (28.9% vs. 52.6%; p = 0.015), and 6 months (20.3% vs. 33.8%; p = 0.002). Repeated‐measures analyzes showed significant time‐by‐limb interactions for sensory ( p = 0.003), lower‐extremity sensory ( p = 0.018), and motor domains ( p = 0.041). Sensory CIPN20 scores were lower in compression limbs in the upper extremities from EOT onward (7.5 vs. 10.2; p < 0.001) and in the lower extremities at 3‐month (8.7 vs. 10.7; p < 0.001) and 6‐month follow‐up (7.0 vs. 10.0; p < 0.001). EORTC QLQ‐CIPN20 sensory scores identified grade ≥ 2 neuropathy with AUC values > 0.92 at all time points. Dual‐site mechanical compression was associated with reduced incidence and persistence of CIPN. As a low‐cost and scalable intervention, this strategy may improve treatment tolerability and survivorship outcomes. Trial Registration: ClinicalTrials.gov identifier: NCT07105553

6 June 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
KBKADRİYE BAŞKURT
KADRİYE BAŞKURT
OAOrhun Akdoğan
Orhun Akdoğan
YKYasemin Sağdıç Karateke
Yasemin Sağdıç Karateke
İOİlknur Deliktaş Onur
İlknur Deliktaş Onur
GUGalip Uyar
Galip Uyar
OSOsman Sutcuoglu
Osman Sutcuoglu
Short-term mortality following the last dose of immune checkpoint inhibitors (ICIs) is an increasingly recognized real-world outcome measure, yet its clinical predictors remain poorly characterized. This multicenter retrospective study included 458 consecutive patients with advanced melanoma, non-small cell lung cancer, or renal cell carcinoma who received ICIs at four tertiary centers in Turkey between 2018 and 2023. The primary endpoint was 30-day mortality after the final ICI dose. Among 458 patients, 71 (15.5%) died within 30 days. Multivariable logistic regression identified ECOG performance status ≥ 2, number of metastatic sites ≥ 3, and log-transformed C-reactive protein-to-albumin ratio (log-CAR) as independent predictors of 30-day mortality in Model 1 (AUC 0.954), while ECOG PS ≥ 2, brain metastasis, metastatic sites ≥ 3, and log-NLR were independent predictors in Model 2 (AUC 0.912). In the lung cancer subgroup, log-CAR and NLR remained independent predictors while ECOG PS did not. Patients who died within 30 days had significantly shorter progression-free survival (1.18 vs. 4.63 months) and overall survival (2.30 vs. 14.39 months) compared with survivors. These findings suggest that routine assessment of inflammatory and nutritional biomarkers alongside tumor burden parameters may help identify patients at high risk of early mortality and inform the timing of supportive care in ICI-treated populations.